A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV

Summary

This is a prospective, open-label, follow up study to protocol 101/2 - continued treatment by IPL344 IV administered once a day in up to 15 participants with ALS. The study is designed to determine the safety, tolerability and initial efficacy of IPL344, administered once a day, by IV infusion for up to 36 months

Timeline

Start

2018-12-09

Primary completion

2027-01

Completion

2027-02

Outcome

Outcome not reported

Stopped: “Study was suspended due to IPL344 shortage and may resume once drug supply is available. Survival follow-up is still ongoing following participants' consent”

Drugs

Indications